<!-- source: https://claude.com/resources/guides/the-enterprise-ai-transformation-guide-for-life-sciences/lay-the-foundation -->

Chapter 0210 min read

# Step 1: Lay the foundation

10 min read

32 min remaining

Driving AI adoption across a life sciences organization starts with deliberate groundwork. In this section we cover how to define your strategy around life sciences use cases, build alignment among scientific, regulatory, and technical stakeholders, and establish governance that meets GxP, FDA, and EU AI Act requirements.

## Driving leadership and stakeholder alignment

Leaders need to understand both the opportunity, including [20 to 30 percent gains (opens in new tab)](https://www.pwc.com/us/en/tech-effect/ai-analytics/ai-predictions.html) in productivity and large reductions in documentation time, and the challenges, including upfront investment, regulatory complexity, data integration hurdles, and the need to keep scientific judgment at the center of every result.

### Build a coalition across stakeholders

In life sciences, stakeholder alignment means securing support from, among others:

* **Executive leadership** (CEO, CFO, COO) who control resources and set strategic priorities
* **Scientific leadership** (CSO, VP of R&D, Head of Computational Biology) who understand research realities and influence scientific teams
* **Clinical and regulatory leadership** (VP of Clinical Operations, Head of Regulatory Affairs, Head of Clinical Data Management) who own the path to submission
* **IT leadership** (CIO, CISO) who manage technical infrastructure and security
* **Compliance and quality teams** who ensure GxP and regulatory adherence
* **Bench scientists, bioinformaticians, and regulatory specialists** who will ultimately decide whether AI tools succeed or fail

Technology alone cannot drive adoption in science. People and scientific workflows have to evolve alongside it. Organizations that treat change management as an afterthought struggle with adoption, especially when scientists see AI as adding work rather than removing it.

### Assemble your AI steering committee

Successful change management starts with a steering committee that represents critical functions and holds real decision-making authority. Include a C-suite sponsor who can clear organizational obstacles, functional leaders who understand operational realities, technology executives who grasp implementation requirements, finance representatives who track ROI and budgets, and legal or compliance leaders who can set governance.

### Prioritize deep listening

The most successful AI rollouts begin with listening rather than technology evangelism. Where do your scientists lose time to manual assembly work? Which workflows feel broken? What keeps regulatory teams compiling submissions late into the night?

Starting with these pain points rather than the technology builds trust and makes sure your strategy addresses real needs. When scientists see that AI targets the problems that frustrate them daily, they become advocates rather than skeptics.

### Address scientific skepticism directly

Scientists, bioinformaticians, and regulatory specialists have seen plenty of tools that promised to make their lives easier and instead added burden. That history creates legitimate skepticism, and it deserves a direct response.

* Acknowledge past technology disappointments rather than ignoring them
* Commit to measuring actual impact on scientific workflows, not just technical metrics
* Give scientists clear ways to give feedback and shape the rollout
* Commit to sunsetting applications that don't deliver
* Make clear that AI enhances scientific judgment, it doesn't replace it

This honest engagement builds credibility. Scientists respect leaders who flag the hard parts early instead of overpromising.

### Develop AI implementation champions

Beyond the steering committee, identify and empower champions at every level. These are respected managers who influence their peers, technical experts who understand both legacy systems and AI, early adopters who bring energy, and thoughtful skeptics whose questions surface real risks. Give champions extra training, direct access to leadership, and recognition that makes their advocacy visible across the organization.

## Regulatory alignment

Life sciences AI governance has to address frameworks that other industries never encounter, so it's important to build compliance into your architecture from day one. Retrofitting it after deployment is costly and sometimes impossible without rebuilding. Below are the governance frameworks most likely to apply to life sciences organizations.

### GxP and 21 CFR Part 11

Software that supports regulated development and manufacturing must meet Good Practice (GxP) expectations and, for electronic records and signatures, [21 CFR Part 11 (opens in new tab)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application). In practice that means validated systems, controlled changes, and complete audit trails. Build for it from the start:

* **Validation** appropriate to the system's risk, with documented evidence that it does what it's intended to do
* **Audit trails** that are tamper-evident, attributable, and readily searchable, showing who did what and when
* **Data integrity** that meets ALCOA+ principles so records stay attributable, legible, contemporaneous, original, and accurate
* **Change control** that documents and reviews modifications before they reach a regulated environment

### FDA oversight considerations

[AI that meets the definition of a medical device (opens in new tab)](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device), including software as a medical device (SaMD), requires FDA clearance or approval before deployment. Even if your first applications don't qualify, plan your governance with future oversight in mind. Key considerations include pre-market submission requirements, clinical validation, labeling, post-market surveillance, adverse-event reporting, and managing modifications under a predetermined change control plan.

### EU AI Act compliance

For organizations operating in Europe or serving European patients, the EU AI Act classifies certain life sciences AI systems as "[high-risk (opens in new tab)](https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence)," which triggers extensive requirements:

* **Risk management systems** with documented assessments and mitigations across the system lifecycle
* **Data governance** that keeps training and reference data relevant, representative, and free from bias
* **Technical documentation** maintained throughout the lifecycle, covering design, data characteristics, testing, change logs, and instructions for use
* **Human oversight** built into the architecture so people can interpret outputs, override them when needed, and are trained to do so
* **Robustness, accuracy, and cybersecurity** appropriate to high-risk systems, with monitoring after deployment

### Data privacy in clinical research

When AI touches patient data in clinical trials or real-world evidence, privacy frameworks may apply, including GDPR in Europe and HIPAA in the United States. Make sure you have appropriate agreements with vendors who access protected data, encryption in transit and at rest, role-based access, and breach-notification procedures. Treat patient data minimization and purpose limitation as design principles, not afterthoughts.

## Establish an AI governance framework

With compliance frameworks in place, you're ready to establish governance that puts them into practice. A good framework enables innovation while managing risk through policies that balance protection with productivity. Key components include:

* **Access controls** that determine who can use AI systems and what data they can reach, with role-based permissions aligned to responsibilities and data sensitivity
* **Usage guidelines** that clarify acceptable applications and explicitly prohibit problematic ones, such as putting confidential IP or patient data into public AI models or making consequential decisions without human review
* **Quality standards** that set review requirements and accuracy thresholds, defining when outputs need human verification and when they can proceed
* **Compliance protocols** that meet regulatory requirements across jurisdictions, from GDPR to FDA regulations and GxP standards

The earlier you prioritize governance, the more durable your AI program will be. Governance is core to how Anthropic builds. We were one of the first AI companies to earn [ISO 42001 certification (opens in new tab)](https://www.anthropic.com/news/anthropic-achieves-iso-42001-certification-for-responsible-ai) for responsible AI, and we publish the policies, evaluations, and risk reports behind our models so customers can hold us to them. Many life sciences customers have found these resources useful:

* The [Responsible Scaling Policy (opens in new tab)](https://www.anthropic.com/responsible-scaling-policy), our voluntary framework for assessing and mitigating catastrophic risks as model capabilities advance — structurally similar to the biosafety levels that already govern lab work
* The [Trust Center (opens in new tab)](https://trust.anthropic.com/), where we publish certifications, sub-processors, and data-handling commitments, including the availability of HIPAA-eligible offerings to customers who execute a Business Associate Agreement
* The [Transparency Hub (opens in new tab)](https://www.anthropic.com/transparency/system-trust-reporting), with enforcement data, legal request handling, and detail on how we approach user safety
* [Claude's Constitution (opens in new tab)](https://www.anthropic.com/news/claudes-constitution), which details the principles that guide Claude's behavior
